


Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 11/01/2025
Policy Number: PA.CP.PHAR.648	Effective Date: 12/2023 Revision Date: 10/2025
Policy Name: Rozanolixizumab-noli (Rystiggo)	
<p>Type of Submission – <u>Check all that apply</u>:</p> <p> <input type="checkbox"/> New Policy <input checked="" type="checkbox"/> Revised Policy* <input type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> </p>	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any changes or clarifying information for the policy below:</p> <p>4Q 2025 annual review: for gMG, clarified that the required immunosuppressive therapy should be non-steroidal; extended approval durations from 6 to 12 months as gMG is a chronic condition; references reviewed and updated.</p>	
Name of Authorized Individual (Please type or print): Craig A. Butler, MD MBA	Signature of Authorized Individual: 

Clinical Policy: Rozanolixizumab-noli (Rystiggo)

Reference Number: PA.CP.PHAR.648

Effective Date: 12/2023

Last Review Date: 10/2025

Description

Rozanolixizumab-noli (Rystiggo[®]) is a neonatal Fc receptor blocker.

FDA Approved Indication(s)

Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness[®] that Rystiggo is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Generalized Myasthenia Gravis (must meet all):

1. Diagnosis of gMG;
2. Prescribed by or in consultation with a neurologist;
3. Age \geq 18 years;
4. Myasthenia Gravis-Activities of Daily Living (MG-ADL) \geq 3 from non-ocular symptoms at baseline;
5. Myasthenia Gravis Foundation of America (MGFA) clinical classification of Class II to IVa;
6. Member has positive serologic test for one of the following (a or b):
 - a. Anti-AChR antibodies;
 - b. Anti-MuSK antibodies;
7. If member has positive serologic test for anti-AChR antibodies: Failure of a cholinesterase inhibitor (*see Appendix B*), unless contraindicated or clinically significant adverse effects are experienced;
8. Failure of a corticosteroid (*see Appendix B*), unless contraindicated or clinically significant adverse effects are experienced;
9. Failure of at least one non-steroidal immunosuppressive therapy (*see Appendix B*), unless clinically significant adverse effects are experienced or all are contraindicated;
10. Rystiggo is not prescribed concurrently with Vyvgart[®], Vyvgart[®] Hytrulo, Soliris[®]/Bkmv[™]/Epysqli[®], Ultomiris[®] or Zilbrysq[®];
11. Documentation of member's current weight (in kg);
12. Dose does not exceed both of the following (a and b) once weekly for the first 6 weeks of every 9-week cycle:
 - a. One of the following (i, ii or iii):
 - i. Weight < 50 kg: 420 mg;

- ii. Weight 50 kg to < 100 kg: 560 mg;
- iii. Weight \geq 100 kg: 840 mg;
- b. 1 vial.

Approval duration: 12 months

B. Other diagnoses/indications

- 1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

II. Continued Therapy

A. Generalized Myasthenia Gravis (must meet all):

- 1. Currently receiving medication via PA Health & Wellness benefit or member has previously met all initial approval criteria or the Continuity of Care policy (PA.PHARM.01) applies; Member is responding positively to therapy;
- 2. Member is responding positively to therapy as evidenced by a 2-point reduction in MG-ADL total score from baseline;
- 3. Rystiggo is not prescribed concurrently with Vyvgart, Vyvgart Hytrulo, Soliris/Bkemv/Epysqli, Ultomiris or Zilbrysq;
- 4. Documentation of member's current weight (in kg);
- 5. If request is for a dose increase, new dose does not exceed both of the following (a and b) once weekly for the first 6 weeks of every 9-week cycle:
 - a. One of the following (i, ii, or iii):
 - i. Weight < 50 kg: 420 mg;
 - ii. Weight 50 kg to < 100 kg: 560 mg;
 - iii. Weight \geq 100 kg: 840 mg;
 - b. 1 vial.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

- 1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.PHARM.01) applies.

Approval duration: Duration of request or 12 months (whichever is less); or

- 2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AChR: acetylcholine receptor

FDA: Food and Drug Administration

gMG: generalized myasthenia gravis
 MG-ADL: Myasthenia Gravis-Activities
 of Daily Living

MGFA: Myasthenia Gravis Foundation
 of America
 MuSK: muscle-specific tyrosine kinase

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Corticosteroids		
betamethasone	Oral: 0.6 to 7.2 mg PO per day	7.2 mg/day
dexamethasone	Oral: 0.75 to 9 mg/day PO	9 mg/day
methylprednisolone	Oral: 12 to 20 mg PO per day; increase as needed by 4 mg every 2-3 days until there is marked clinical improvement	40 mg/day
prednisone	Oral: 15 mg/day to 20 mg/day; increase by 5 mg every 2-3 days as needed	60 mg/day
Cholinesterase Inhibitors		
pyridostigmine (Mestinon®)	Oral immediate-release: 600 mg daily in divided doses (range, 60-1,500 mg daily in divided doses) Oral sustained release: 180-540 mg QD or BID	Immediate-release: 1,500 mg/day Sustained-release: 1,080 mg/day
neostigmine (Bloxiverz®)	Oral: 15 mg TID. The daily dosage should be gradually increased at intervals of 1 or more days. The usual maintenance dosage is 15-375 mg/day (average 150 mg) IM or SC: 0.5 mg based on response to therapy	Oral: 375 mg/day
Nonsteroidal Immunosuppressants		
azathioprine (Imuran®)	Oral: 50 mg QD for 1 week, then increase gradually to 2 to 3 mg/kg/day	3 mg/kg/day
mycophenolate mofetil (Cellcept®)*	Oral: Dosage not established. 1 gram BID has been used with adjunctive corticosteroids or other non-steroidal immunosuppressive medications	2 g/day
cyclosporine (Sandimmune®)*	Oral: initial dose of cyclosporine (non-modified), 5 mg/kg/day in 2 divided doses	5 mg/kg/day
Rituxan® (rituximab), Riabni™ (rituximab-arrx), Ruxience™ (rituximab-pvvr), Truxima® (rituximab-abbs)*†	IV: 375 mg/m ² once a week for 4 weeks; an additional 375 mg/m ² dose may be given every 1 to 3 months afterwards	375 mg/m ²

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

**Off-label*

†Prior authorization is required for rituximab products

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- The MGFA stratifies patients by the extent and severity of muscle weakness. The classification has some subjectivity in it when it comes to distinguishing mild (Class II) from moderate (Class III) and moderate (Class III) from severe (Class IV). Furthermore, it is insensitive to change from one visit to the next.
 - The degree of impairment in Class IVa is predominantly in the limb and/or axial muscles whereas impairment in Class IVb is predominantly in the oropharyngeal and/or respiratory muscles. The clinical classification can be accessed here: <https://myasthenia.org/Portals/0/MGFA%20Classification.pdf>
- The MG-ADL scale is an 8-item patient-reported scale that measures functional status in 8 domains related to MG – talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop. Each domain is given a score of 0-3, with 0 being normal and 3 being most severe impairment. A 2-point decrease in the MG-ADL score is considered a clinically meaningful response. The scale can be accessed here: <https://myasthenia.org/Portals/0/ADL.pdf>

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
gMG	<p>Initial dosage is administered as SC infusion once weekly for 6 weeks based on body weight:</p> <ul style="list-style-type: none"> • < 50 kg: 420 mg • 50 kg to < 100 kg: 560 mg • ≥ 100 kg: 840 mg <p>Subsequent treatment cycles administered based on clinical evaluation; the safety of initiating subsequent cycles sooner than 63 days from the start of the previous treatment cycle has not been established.</p>	840 mg/week

VI. Product Availability

Single-dose vials: 280 mg/2 mL (140 mg/mL), 420 mg/3 mL (140 mg/mL), 560 mg/4 mL (140 mg/mL), 840 mg/6 mL (140 mg/mL)

VII. References

1. Rystiggo Prescribing Information. Smyrna, GA: UCB; March 2025. Available at: <https://www.ucb-usa.com/RYSTIGGO-prescribing-information.pdf>. Accessed July 17, 2025.

2. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. *Lancet Neurol.* 2023;22(5):383-394.
3. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. *Neurology* 2016;87:419-425.
4. Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis 2020 update. *Neurology* 2021;96:114-22.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9333	Injection, rozanolixizumab-noli, 1 mg

Reviews, Revisions, and Approvals	Date
Policy created	10/2023
4Q 2024 annual review: RT4: added new 420 mg/3 mL, 560 mg/4 mL, and 840/6 mL volume formulations and updated all quantity limits to 1 vial; added Bkemy, Epysqli, and Zilbrysq to the list of therapies that Rystiggo should not be prescribed concurrently with; J9333; references reviewed and updated.	10/2024
4Q 2025 annual review: for gMG, clarified that the required immunosuppressive therapy should be non-steroidal; extended approval durations from 6 to 12 months as gMG is a chronic condition; references reviewed and updated.	10/2025